Cantor Fitzgerald raised target for Amgen stock from USD 400.00 to USD 440.00

Published on 10/12/2026 at 11:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cantor raised its target to USD 440.00 on October 8, 2026. Amgen stock costs EUR 370.65 on October 12, 2026 as Q2 revenue hit USD 10.05 billion.

Key points in brief

Cantor Fitzgerald raised its Amgen price target from USD 400.00 to USD 440.00 on October 8, 2026.
Amgen's second-quarter 2026 revenue reached USD 10.05 billion, up 9.50 percent year over year.
The Lang & Schwarz price was EUR 370.65 on October 12, 2026 at 11:38 a.m. CEST.
Amgen is listed on the NASDAQ and is included in the Nasdaq-100 Index.

Architektonischer 3D-Render eines modernen Biopharma-Gebäudes mit Glasfassade und gepflegter Grünanlage — Amgen Inc. (ISIN US0311621009) passend visualisiert als architektonischer Render einer modernen Biopharma-Forschungsanlage, Illustration mit AI erstellt.

Amgen (US0311621009) was priced at EUR 370.65 at Lang & Schwarz on October 12, 2026 at 11:38 a.m. CEST, while Cantor Fitzgerald had raised its target from USD 400.00 to USD 440.00 on October 8, 2026, according to Markets Insider. The Neutral rating stayed unchanged, making the target increase a more measured signal than a formal upgrade.

Three milestones shape the pipeline

Amgen reported USD 10.05 billion in revenue for the second quarter of 2026 on August 4, 2026, up 9.50 percent from the same quarter a year earlier. Net income reached USD 2.38 billion, up 65.90 percent, while diluted earnings per share rose 64.90 percent to USD 4.37, according to Ticker Scout.

On September 22, 2026, Amgen said its Phase 3 OASIZ 301 study of dazodalibep met its primary endpoint after 48 weeks. The company also said improvements appeared as early as Week 4 and that OASIZ 303 was expected to complete in the fourth quarter of 2026, according to Amgen.

On October 8, 2026, Cantor Fitzgerald raised its Amgen target from USD 400.00 to USD 440.00 while retaining a Neutral rating, according to Markets Insider. Cantor linked the case to continued commercial performance through the second half of 2026 and to the timing of MariTide data in the first half of 2027.

What does the target change mean?

The target increase sits against a business growing faster in profit than in sales. Second-quarter revenue rose 9.50 percent, but net income advanced 65.90 percent, a gap that reflects the importance of product mix, cost structure and acquisition-related accounting items.

The valuation backdrop is substantial. Amgen's market capitalization was USD 223.9 billion at the October 9, 2026 Nasdaq quote, while the stock's 52-week range was USD 288.00 to USD 447.03. The Lang & Schwarz euro quotation cannot be netted against that dollar range, so the two figures remain separate market references.

Next date on the calendar

TradingView lists November 3, 2026 as the next Amgen reporting date for the third quarter of 2026. That release will test whether the second-quarter revenue trajectory and the pipeline narrative remain aligned with the higher analyst targets.

Amgen was last quoted at USD 414.87 on Nasdaq on October 9, 2026 at 4:00 p.m. EDT. The company is included in the Dow Jones Industrial Average and the Nasdaq-100 Index. The further course of trading is shown by the continuously updated real-time quote of Amgen stock.